GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amylyx Pharmaceuticals Inc (NAS:AMLX) » Definitions » EBITDA Margin %

Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) EBITDA Margin % : 2.06% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Amylyx Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Amylyx Pharmaceuticals's EBITDA for the three months ended in Dec. 2023 was $2.2 Mil. Amylyx Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $108.4 Mil. Therefore, Amylyx Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2023 was 2.06%.


Amylyx Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Amylyx Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amylyx Pharmaceuticals EBITDA Margin % Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - -903.53 10.48

Amylyx Pharmaceuticals Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -202.93 -2.59 20.85 18.52 2.06

Competitive Comparison of Amylyx Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Amylyx Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amylyx Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Amylyx Pharmaceuticals's EBITDA Margin % falls into.



Amylyx Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Amylyx Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=39.89/380.786
=10.48 %

Amylyx Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=2.235/108.449
=2.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amylyx Pharmaceuticals  (NAS:AMLX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Amylyx Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amylyx Pharmaceuticals (Amylyx Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
43 Thorndike Street, Cambridge, MA, USA, 02141
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.
Executives
Joshua B Cohen director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Justin B. Klee director, officer: Co-Chief Executive Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486
James M Frates officer: Chief Financial Officer 88 SIDNEY ST, CAMBRIDGE MA 021394136
Karen Firestone director C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141
Gina Mazzariello officer: Chief Legal Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Morningside Venture Investments Ltd 10 percent owner MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Milne George M Jr director
Margaret Olinger officer: Chief Commercial Officer C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 96 Llc 10 percent owner 55 RAILROAD AVE., GREENWICH CT 06830
Als Invest 1 B.v. 10 percent owner EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017
Isaac Cheng director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Mvil, Llc 10 percent owner 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901